By Carla K. Johnson

A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.

Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.

They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.

“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”

The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.

Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.

In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.

The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.

Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.

The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.

The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Americans Stress Out Over Inflation, War
A new study shows that Americans feel record levels of stress amid inflation and global uncertainty about the war in Ukraine. Cheddar News speaks with Lynn Bufka of the American Psychological Association about how to best put your worries aside.
Colgate-Palmolive To Invest $100 Million Over Five Years In Oral Health Initiative
Colgate-Palmolive is shedding light on the little-known fact that oral health is integral to overall health. The consumer products company will commit $100 million over five years to transform the way the world thinks about and addresses oral health. Maria Ryan, Chief Clinical Officer at Colgate-Palmolive, discusses why oral health is so vital to our physical and mental well-being.
Concerns Grow After Russian Shelling and Seizure of Ukraine Nuclear Plant
News of Russian forces taking control of a Ukrainian after artillery bombardment of a nuclear power plant raised concerns this week. Nuclear policy expert and Quincy Institute Distinguished Fellow Joe Cirincione joined Cheddar News to discuss the implications for a potential disaster. “I’m with the director general of the IAEA, the International Atomic Energy Agency. He says that he is extremely concerned, and that this Russian attack is a severe risk and that Russia clearly violated the fundamental principle of preserving the integrity of nuclear power plants," Cirincione said.
Space Junk Set to Crash Into Moon
Adam Battle, research assistant at University of Arizona's Lunar and Planetary Laboratory, joins Cheddar News to discuss space junk heading to the moon and if more should be done to prevent space junk in the future.
Study Shows Corn-Based Ethanol Could Be Worse for Climate Than Gasoline Alone
Under the U.S. Renewable Fuel Standard (RFS), corn-based ethanol has been mixed into gasoline sold at pumps in the U.S. since 2005, when a policy was enacted aimed at reducing emissions. Corn-based ethanol had been thought to be a relatively greener energy source compared to other biofuels, but now, a new study published in the Proceedings of the National Academy of Sciences reports it may be actually worse for the climate than straight gasoline. Tyler Lark, an assistant scientist at the University of Wisconsin-Madison's Center for Sustainability, joined Cheddar News' Closing Bell and discussed the pushback against the study. "Essentially when you need to produce more corn to meet the demand for use as ethanol as fuel, farmers respond and they switch more crops like soybeans and wheat into corn," Lark said. "They also bring more land into production, so things that used to be pasture grassland, and both those activities are associated with increased greenhouse gas emissions."
Load More